Arcus Biosciences, Inc. Payments to Acquire Investments
Arcus Biosciences, Inc. (RCUS) reported Payments to Acquire Investments of $1.09 billion for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2022-11-02
- Arcus Biosciences, Inc. payments to acquire investments for the quarter ending 2022-09-30 was $322.26M, a 50.48% increase year-over-year.
- Arcus Biosciences, Inc. payments to acquire investments for the quarter ending 2022-06-30 was $385.56M, a 116.25% increase year-over-year.
- Arcus Biosciences, Inc. payments to acquire investments for the quarter ending 2022-03-31 was $377.57M, a 96.25% increase year-over-year.
- Arcus Biosciences, Inc. payments to acquire investments for the quarter ending 2021-12-31 was $134.01M, a 21.52% decline year-over-year.
- Arcus Biosciences, Inc. payments to acquire investments for fiscal 2021 was $718.87M, a 2.81% decline from fiscal 2020.
- Arcus Biosciences, Inc. payments to acquire investments for fiscal 2020 was $739.66M, a 198.54% increase from fiscal 2019.
- Arcus Biosciences, Inc. payments to acquire investments for fiscal 2019 was $247.75M, a 5.28% decline from fiscal 2018.
- Arcus Biosciences, Inc. payments to acquire investments for fiscal 2018 was $261.55M, a 170.11% increase from fiscal 2017.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2022-09-30 | $322.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $707.82M derived: sum of 2 quarters · filed 2022-11-02 | $1.09B 10-Q · filed 2022-11-02 | $1.22B derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | $385.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $763.13M 10-Q · filed 2022-08-03 | $897.15M derived: sum of 3 quarters · filed 2022-08-03 | $1.11B derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | $377.57M 10-Q · filed 2022-05-09 | $511.59M derived: sum of 2 quarters · filed 2022-05-09 | $725.75M derived: sum of 3 quarters · filed 2022-11-02 | $904.04M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | $134.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $348.18M derived: sum of 2 quarters · filed 2022-11-02 | $526.47M derived: sum of 3 quarters · filed 2022-11-02 | $718.87M 10-K · filed 2022-02-23 |
| 2021-09-30 | $214.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $392.45M derived: sum of 2 quarters · filed 2022-11-02 | $584.85M 10-Q · filed 2022-11-02 | $755.61M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $178.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $370.69M 10-Q · filed 2022-08-03 | $541.45M derived: sum of 3 quarters · filed 2022-08-03 | $970.66M derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-31 | $192.40M 10-Q · filed 2022-05-09 | $363.15M derived: sum of 2 quarters · filed 2022-05-09 | $792.37M derived: sum of 3 quarters · filed 2022-05-09 | $923.17M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $170.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $599.97M derived: sum of 2 quarters · filed 2022-02-23 | $730.77M derived: sum of 3 quarters · filed 2022-02-23 | $739.66M 10-K · filed 2022-02-23 |
| 2020-09-30 | $429.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $560.02M derived: sum of 2 quarters · filed 2021-11-08 | $568.90M 10-Q · filed 2021-11-08 | $636.41M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $130.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $139.69M 10-Q · filed 2021-08-05 | $207.20M derived: sum of 3 quarters · filed 2022-02-23 | $263.61M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $8.88M 10-Q · filed 2021-05-05 | $76.39M derived: sum of 2 quarters · filed 2022-02-23 | $132.80M derived: sum of 3 quarters · filed 2022-02-23 | $184.23M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $67.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $123.92M derived: sum of 2 quarters · filed 2022-02-23 | $175.35M derived: sum of 3 quarters · filed 2022-02-23 | $247.75M 10-K · filed 2022-02-23 |
| 2019-09-30 | $56.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $107.84M derived: sum of 2 quarters · filed 2020-11-05 | $180.25M 10-Q · filed 2020-11-05 | $219.73M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $51.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $123.84M 10-Q · filed 2020-08-06 | $163.32M derived: sum of 3 quarters · filed 2021-02-25 | $294.72M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $72.41M 10-Q · filed 2020-05-05 | $111.89M derived: sum of 2 quarters · filed 2021-02-25 | $243.29M derived: sum of 3 quarters · filed 2021-02-25 | $292.88M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $39.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $170.88M derived: sum of 2 quarters · filed 2021-02-25 | $220.47M derived: sum of 3 quarters · filed 2021-02-25 | $261.55M 10-K · filed 2021-02-25 |
| 2018-09-30 | $131.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $180.98M derived: sum of 2 quarters · filed 2019-11-05 | $222.07M 10-Q · filed 2019-11-05 | $281.18M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $49.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $90.67M 10-Q · filed 2019-08-06 | $149.78M derived: sum of 3 quarters · filed 2019-08-06 | $156.06M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $41.08M 10-Q · filed 2019-05-02 | $100.20M derived: sum of 2 quarters · filed 2019-05-02 | $106.47M derived: sum of 3 quarters · filed 2019-05-02 | $116.56M derived: sum of 4 quarters · filed 2019-05-02 |
| 2017-12-31 | $59.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $65.39M derived: sum of 2 quarters · filed 2019-03-05 | $75.48M derived: sum of 3 quarters · filed 2019-03-05 | $96.83M 10-K · filed 2019-03-05 |
| 2017-09-30 | $6.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $16.36M derived: sum of 2 quarters · filed 2018-11-08 | $37.72M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $10.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $31.44M 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | $21.35M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $33.76M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |